Mixed Responses To BioCryst's Oral Phase III HAI Therapy, BCX7353
Executive Summary
BioCryst’s BCX7353 could be the first oral therapy to prevent hereditary angioedema attacks, but it might not work in all patients, according to data from the Phase III APeX-2 study.
You may also be interested in...
BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Finance Watch: Big Money For Big Goals Met By Reata, CRISPR, Karuna
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
BioCryst’s Oral Therapy For HAE Attacks On Track With Exploratory Phase II Success
Biocryst’s oral kallikrein inhibitor BCX7353 – already in Phase III for prophylaxis of hereditary angioedema – shows efficacy in a range of endpoints in a Phase II exploratory trial.